Table 2. Effects of compounds on inhibition of SS cell sickling, oxygen affinity and Hb S adduct formation.
Compound | Concentration (mM) | Inhibition of sickling cells (%) | HbS ΔP50† (%) | Hb S adductformation (%) |
---|---|---|---|---|
INN-312 | 0.5 | 15 ± 2 | 24.8 ± 5.2 | 34 ± 2.2 |
INN-312 | 1 | 44 ± 10 | 49.2 ± 5.3 | 79 ± 2.7 |
INN-312 | 2 | 95 ± 9 | 75.8 ± 7.9 | 100 ± 4.9 |
INN-298 | 0.5 | 18 ± 5 | 7.5 | 35 |
INN-298 | 1 | 48 ± 7 | 24.7 | 55 |
INN-298 | 2 | 80 ± 11 | 64.5 | 100 |
Vanillin | 2 | 0.8 ± 0.2 | 15 ± 1.9 | 11.7 ± 3.5 |
Vanillin | 5 | 12 ± 0.4 | 40 ± 9.5 | 40 ± 4.3 |
ΔP 50 = [P 50(control) − P 50(sample)]/P 50(control) expressed as a percentage. An OEC study of several INN compounds (at 5 mM concentration) with normal blood (40% hematocrit) has previously been reported (Nnamani et al., 2008 ▶).